EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice

David T Luong iD, Chenchen Niu, Eunice Kim, Nolan Tanji iD, Ivy Duong iD, Brandon Galero iD, Yong-Jie Zhang iD, Craig L Bennett iD, Albert R La Spada

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27041820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von David T Luong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, PPAR delta, C9orf72 Protein, DNA-Binding Proteins. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome-proliferator–activated receptor delta (PPARδ) regulates metabolic, mitochondrial, and inflammatory pathways implicated in neurodegeneration, making it an attractive therapeutic target for amyotrophic lateral sclerosis (ALS). In this study, we evaluated two PPARδ agonists, KD3010 and T3D-959, in two established ALS/FTD mouse models: an AAV-mediated C9orf72 G4C2-repeat expansion model (C9-149R) and the TDP-43Q331K transgenic model. Drug treatment was initiated prior to the emergence of key disease features and continued for 9–10 months. Comprehensive behavioral, neuropathological, and biomarker analyses revealed marked differences between the two models. C9-149R mice exhibited reduced body weight and subtle behavioral alterations without robust motor deficits, whereas TDP-43Q331K mice developed pronounced, progressive motor and cognitive impairments accompanied by a ~7-fold elevation in plasma neurofilament light chain (NfL). Despite effective target engagement—particularly for T3D-959—neither PPARδ agonist improved motor performance, cognitive behavior, neuroanatomical measures, plasma NfL levels, or disease-associated molecular phenotypes in either model. Prolonged KD3010 treatment resulted in loss of target engagement, consistent with drug tolerance, while T3D-959 sustained PPARδ activation without therapeutic benefit. Together, these findings demonstrate that PPARδ agonism is insufficient to modify disease progression in these ALS/FTD mouse models and underscore the importance of publishing well-powered negative preclinical studies to refine therapeutic strategies for ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisPPAR deltaC9orf72 ProteinDNA-Binding ProteinsAnimalsMiceDisease Models, AnimalMice, TransgenicPhenotypeHumansMaleNeurofilament Proteins

Stichwörter der Autor:innen

AAV-149RC9orf72KD3010PPARδT3D-959TDP-43amyotrophic lateral sclerosisdipeptide repeatneurofilament light chain

Substanzen

PPAR deltaC9orf72 ProteinDNA-Binding ProteinsNeurofilament ProteinsTardbp protein, mouseneurofilament protein L

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA.
  • Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • UCI Center for Neurotherapeutics, University of California, Irvine, CA 92697, USA.
  • Department of Neurology, University of California, Irvine, CA 92697, USA.
  • Department of Biological Chemistry, University of California, Irvine, CA 92697, USA.
  • Department of Neurobiology and Behavior, University of California, Irvine, CA 92697, USA.

ORCID-Profile: David T Luong, Nolan Tanji, Ivy Duong, Brandon Galero, Yong-Jie Zhang, Craig L Bennett

Förderung

  • United States Department of Defense
  • U.S. Department of Defense

Zitieren

APA

Luong, D. T., Niu, C., Kim, E., Tanji, N., Duong, I., Galero, B., Zhang, Y. J., Bennett, C. L., & La Spada, A. R. (2026). PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041820

Vancouver

Luong DT, Niu C, Kim E, Tanji N, Duong I, Galero B, et al. PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041820

BibTeX
@article{Luong2026,
  author = {Luong, David T and Niu, Chenchen and Kim, Eunice and Tanji, Nolan and Duong, Ivy and Galero, Brandon and Zhang, Yong-Jie and Bennett, Craig L and La Spada, Albert R},
  title = {PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27041820}
}
Kostenlos starten →